Beyond Airの空売り状況は、投資家がBeyond Airの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Beyond Air (NASDAQ:XAIR) 株価情報, 空売り情報

Beyond Air

Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Beyond Air Inc

WIIM

CTOR

Citius Oncology shares are trading higher after the company said it expects the commercial launch LYMPHIR in the second half of 2025.

ABM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>), a leading provider of facility, engineering, and infrastructure solutions, is proud to announce a new five-year partnership valued at approximately $125 million with Miami-Dade County to provide comprehensive janitorial, smart facility, and integrated maintenance services at Miami International Airport ("MIA"). This agreement includes the full deployment of ABM ConnectTM, the company's industry-leading technology and data intelligence platform, including the most integrated Smart Restroom monitoring solution ABM has implemented to date.
Through this new agreement, ABM will serve as a key partner in supporting MIA's <a href="https://www.globenewswire.com/Tracker?data=DLtbzWwPHxo5xt48DpQ3KhGjiCHZwyWClAspM-ozKVtkBTu-TCjloIAK3dmVEHrcuTSmQ1p8CTC295wsMDzCtxq42-pv59BrF21wDZ7w9whsneAr76vQlAbm_RBJD3iLiSksSl_5rZUAOREf8IzStg==">Modernization in Action (M.I.A.) Plan</a> — delivering advanced, data-driven service models that enhance passenger experience, support long-term infrastructure goals, and promote inclusive economic growth in the South Florida region.

News

Contracts

ABM Secures $125M 5-Year Deal With Miami-Dade To Deliver Smart Facility And Maintenance Services At Miami International Airport

SCIENTURE HOLDINGS, INC. (NASDAQ:<a href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced it has terminated its Equity Line of Credit ("ELOC") facility effective as of May 22, 2025.
In connection with cancellation of the ELOC, on June 16, 2025, the Company filed a post-effective amendment to the Registration Statement on Form S-1 (File No. 333-283591) filed with the Securities and Exchange Commission on December 3, 2025, declared effective on February 14, 2025. The post-effective amendment deregisters all 310,488 unsold shares of the Company's common stock that had been registered under the registration statement.
This strategic financial decision comes as the Company prepares to commercially launch its first FDA-approved product candidate, Arbli&#x2122;, which is the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market.
The Company continues to expect that it will commercially launch Arbli&#x2122; by making it available to patients in the U.S. during Q3 2025. Arbli&#x2122; is indicated for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy, and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes.

SCNX

Scienture Holdings Terminates Equity Line Of Credit Facility Effective As Of May 22, 2025

AZTR

Azitra shares are trading higher after the company reported Phase 1b safety data for ATR12-351 in Netherton syndrome, stating it was generally safe and well-tolerated.

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy and maintains $16 price target.

Price Target

Analyst Ratings

FBLG

D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target

Expanded collaboration brings together CXone Mpower, Amazon Q index, Amazon SageMaker, and Amazon Bedrock to accelerate intelligent automation across every role and workflow in the enterprise
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.nice.com&amp;esheet=54276742&amp;newsitemid=20250617558355&amp;lan=en-US&amp;anchor=NiCE&amp;index=1&amp;md5=20cd982f5289babcd78a2e96aef1b6b9">NiCE</a> (NASDAQ:<a href="https://www.benzinga.com/stock/NICE#NASDAQ">NICE</a>) today announced the next evolution of its strategic relationship with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Faws.amazon.com%2F&amp;esheet=54276742&amp;newsitemid=20250617558355&amp;lan=en-US&amp;anchor=Amazon+Web+Services%2C+Inc.&amp;index=2&amp;md5=50126d77bacb58ed6d3723451146985c">Amazon Web Services, Inc.</a> (AWS),announcing a new collaboration to accelerate a shared vision to innovate the development, deployment and scaling of intelligent AI-powered solutions purpose-built for end-to-end customer service automation. Together, NiCE and AWS bring improved enterprise capabilities combining NiCE's leadership in customer service automation, deep domain expertise, and rich interaction data with the power and scale of AWS Cloud and AI services. Leveraging CXone Mpower and the Amazon Nova family of large language models (LLMs) and services such as Amazon Bedrock, Amazon Q, and Amazon SageMaker, this relationship is transforming business operations, driving intelligent automation at scale, accelerating time-to-value, and delivering measurable impact across the front, middle, and back office.
NiCE and AWS will integrate AWS generative AI services across the CXone Mpower platform, delivering intelligent automation that spans every corner of the enterprise. This will unlock enterprise-wide value through the following high-impact use cases:
<ul>
<li>Simplifying AI agent creation with content-aware automation: Mpower Agents generate intelligent AI agents instantly, no code or prompts required—tailored to each business's needs. With Amazon Q index, agents act on the most current policies, product info, and case history to ensure accurate, compliant outcomes. Integration with Amazon SageMaker allows training on rich CX data, letting agents be built from and continuously learn from patterns and top-performers. The result is smarter, faster automation at scale that embodies best practices in customer interaction and process execution.</li>
<li>Driving end-to-end enterprise automation with intelligent orchestration: CXone Mpower Orchestrator automates workflows across the front, middle, and back office, eliminating silos and optimizing operations. By integrating with Amazon Q Business, Orchestrator connects a wider range of systems, applications, and data allowing seamless, personalized and unified customer journeys. Support for the Amazon Nova family of models delivers real-time decisions at key moments with model selection tuned for speed, accuracy, and business impact.</li>
<li>Empowering global teams with AI augmentation: CXone Mpower Copilot delivers real-time, AI-poweredguidance and task support for agents, supervisors and leaders to streamline tasks, boost productivity and support better decision-making across the enterprise. AWS enhances this capability with globally distributed infrastructure, allowing fast, scalable deployment with low latency and high availability anywhere in the world.</li>
</ul>

NICE

NICE Expands AWS Partnership To Accelerate Enterprise-Wide Intelligent Automation With CXone Mpower And Amazon AI Services

Biotech

General

CTXR

Citius Oncology Sees Commercial Launch Of LYMPHIR In Second Half Of 2025

Springview Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) ("Springview Holdings" or the "Company"), a leading designer and builder of residential and commercial properties in Singapore, today announced that its indirect wholly owned Singapore operating subsidiary, Springview Enterprises Pte. Ltd. ("Springview Singapore"), won a major contract worth S$1.725 million for the redevelopment of two units of conservation shop houses in Singapore's Blair Plain Conservation Area. This strategic win underscores Springview Singapore's expanding leadership in heritage-led urban development and reinforces its position as a go-to partner for complex, conservation-driven construction projects.
The contract, awarded by Alpha International Investment Pte Ltd, significantly enhances Springview Singapore's project portfolio and deepens its footprint in the fast-growing urban restoration and infrastructure sectors.
Under the Singapore Institute of Architects' Standard Conditions of Contract, the project is scheduled for completion within 10 calendar months. Springview will oversee all core structural works, regulatory compliance, and cross-disciplinary coordination, ensuring the site meets all requirements for Temporary Occupation Permit (TOP) issuance upon handover.

SPHL

Springview Holdings' Springview Enterprises Bags Major Contract Worth S$1.725M For Redevelopment Of Two Units Of Conservation Shop Houses In Singapore's Blair Plain Conservation Area

GLJ Research analyst Gordon Johnson downgrades Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) from Hold to Sell and maintains the price target from $0.01 to $0.01.

Downgrades

GLJ Research Downgrades Sunrun to Sell, Maintains Price Target to $0.01

La-Z-Boy Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) will release its fourth-quarter earnings results after the <a href="https://www.benzinga.com/quote/LZB/earnings">closing bell on Tuesday, June 17.</a>
Analysts expect the Monroe, Michigan-based company to report quarterly earnings at 93 cents per share, down from 95 cents per share in the year-ago period. According to data from Benzinga Pro, La-Z-Boy projects quarterly revenue of $557.44 million, compared to $553.53 million a year earlier.
On April 25, Keybanc analyst Bradley Thomas upgraded La-Z-Boy from Sector Weight to Overweight and announced a $46 price target.
With the recent buzz around La-Z-Boy, some investors may be eyeing potential gains from the company's dividends too. As of now, La-Z-Boy offers an annual dividend yield of 2.26%, which is a quarterly dividend amount of 22 cents per share (88 cents a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $265,357 or around 6,818 shares. For a more modest $100 per month or $1,200 per year, you would need $53,087 or around 1,364 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($0.88 in this case). So, $6,000 / $0.88 = 6,818 ($500 per month), and $1,200 / $0.88 = 1,364 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
JBL Price Action: Shares of Jabil fell 1.8% to close at $175.84 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45948533/top-2-financial-stocks-that-may-plunge-in-q2">Top 2 Financial Stocks That May Plunge in Q2</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From La-Z-Boy Stock Ahead Of Q4 Earnings

Elicio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>, "Elicio" or the "Company"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, June 25, 2025 at 2:00 PM ET to discuss the significant unmet need and current treatment landscape for mutant-KRAS ("mKRAS") driven pancreatic ductal adenocarcinoma ("PDAC"), one of the most lethal and underserved solid tumors. To register, <a href="https://www.globenewswire.com/Tracker?data=aINq-E0SzlG65dQPESBJa2qGmjF8alw8HAAtv4-WKiH5DbWKgCxkH3yIT_yRDoQcBhVh9AY1LuBM0BaH4Ien_Cob8yXarKkMuphGNe2E7ivJx9j9W3iRSf1ErStPn9nF">click here</a>.
The event will feature insights from leading experts:
<ul>
<li>Darrell Irvine, Ph.D. - Department of Immunology &amp; Microbiology, The Scripps Research Institute, Howard Hughes Medical Institute</li>
<li>Eileen O'Reilly, M.D. - FASCO Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center &nbsp;</li>
</ul>
The event will provide an overview of Elicio's proprietary lymph node-targeting amphiphile ("AMP") platform, which underpins a pipeline of novel immunotherapies designed to generate potent and durable immune responses. The discussion will also focus on Elicio's lead product candidate, ELI-002, an AMP-powered therapeutic vaccine designed to overcome immune evasion. ELI-002 is currently being evaluated in a randomized Phase 2 trial for the adjuvant treatment of mKRAS-driven PDAC, and an event-driven disease-free survival interim analysis of the study is anticipated in Q3 2025.
A live question and answer session will follow the formal presentations.

ELTX

Elicio Therapeutics To Host June 25 Virtual KOL Event At 2:00 PM ET Highlighting Urgent Need And Phase 2 Progress Of AMP-Powered ELI-002 Vaccine For mKRAS-Driven Pancreatic Cancer

<h3>Gainers</h3>
<ul>
<li>Acurx Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACXP#NASDAQ">ACXP</a>) stock moved upwards by 235.5% to $1.03 during Tuesday's pre-market session. The company's market cap stands at $24.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares rose 82.37% to $1.14. The company's market cap stands at $2.4 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares moved upwards by 75.93% to $11.03. The company's market cap stands at $983.3 million. </li>
<li>Azitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock increased by 38.35% to $0.37. The company's market cap stands at $6.1 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares moved upwards by 34.0% to $0.45. The market value of their outstanding shares is at $18.5 million. </li>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) shares increased by 16.66% to $1.75. The market value of their outstanding shares is at $229.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) stock fell 34.8% to $0.21 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Dyne Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) shares decreased by 21.86% to $10.8. The company's market cap stands at $1.2 billion. </li>
<li>Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) shares declined by 20.66% to $0.6. The market value of their outstanding shares is at $72.1 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) shares decreased by 14.99% to $3.63. The market value of their outstanding shares is at $5.0 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock fell 11.06% to $0.3. The market value of their outstanding shares is at $7.2 million. </li>
<li>Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) stock decreased by 9.8% to $20.9. The market value of their outstanding shares is at $2.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACXP

ADIL

CYCC

PRME

PRPH

SGRY

SLRX

SNPX

UNCY

VERV

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) shares increased by 36.3% to $5.48 during Tuesday's pre-market session. The company's market cap stands at $60.8 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) shares increased by 20.83% to $6.67. The company's market cap stands at $15.9 million. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares moved upwards by 11.87% to $1.79. The company's market cap stands at $3.4 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) shares moved upwards by 9.73% to $2.24. The market value of their outstanding shares is at $6.2 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares rose 8.09% to $0.08. The market value of their outstanding shares is at $12.2 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock rose 7.51% to $0.93. The company's market cap stands at $11.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares decreased by 36.0% to $6.17 during Tuesday's pre-market session. The company's market cap stands at $1.4 billion. </li>
<li>CDT Envirn Tech Inv Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) stock fell 17.61% to $1.13. The market value of their outstanding shares is at $13.9 million. </li>
<li>Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) shares decreased by 16.21% to $6.67. The company's market cap stands at $1.0 billion. </li>
<li>Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) stock fell 15.8% to $17.32. The company's market cap stands at $2.1 billion. </li>
<li>Galaxy Payroll Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) stock decreased by 12.33% to $0.43. The company's market cap stands at $7.6 million. </li>
<li>Nextracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) stock fell 11.94% to $53.5. The company's market cap stands at $7.8 billion. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARRY

BGSF

BIYA

CDTG

GLXG

GPUS

RBNE

SOAR

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 19.4% to $0.88 during Tuesday's pre-market session. The company's market cap stands at $47.0 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) shares increased by 16.94% to $2.76. The company's market cap stands at $20.2 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock rose 16.11% to $0.28. The market value of their outstanding shares is at $18.3 million. </li>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) shares moved upwards by 14.44% to $3.17. The company's market cap stands at $19.9 million. </li>
<li>Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) stock rose 12.7% to $22.09. The company's market cap stands at $213.7 million. </li>
<li>DatChat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) shares moved upwards by 9.31% to $3.05. The company's market cap stands at $12.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) stock fell 29.9% to $16.8 during Tuesday's pre-market session. The market value of their outstanding shares is at $991.9 million. </li>
<li>LeddarTech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) stock decreased by 22.0% to $0.16. The company's market cap stands at $6.0 million. </li>
<li>Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) shares fell 20.54% to $36.5. The company's market cap stands at $4.7 billion. </li>
<li>First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares decreased by 16.5% to $146.35. The company's market cap stands at $15.6 billion. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock decreased by 11.5% to $9.01. The company's market cap stands at $150.3 million. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) shares declined by 8.93% to $1.53. The market value of their outstanding shares is at $15.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DATS

ENPH

FEIM

FSLR

LDTC

MINM

MOBX

SEDG

SONM

TDTH

XTIA

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Geospace Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEOS#NASDAQ">GEOS</a>) stock rose 13.5% to $7.82 during Tuesday's pre-market session. The market value of their outstanding shares is at $100.1 million. </li>
<li>Houston American Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#AMEX">HUSA</a>) shares increased by 12.35% to $11.91. The market value of their outstanding shares is at $18.6 million. </li>
<li>Indonesia Energy Corp (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INDO#AMEX">INDO</a>) shares increased by 10.02% to $4.39. The company's market cap stands at $59.7 million. </li>
<li>US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) stock increased by 9.62% to $1.88. The company's market cap stands at $63.9 million. </li>
<li>TMD Energy Limited Ordinary Shares (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#AMEX">TMDE</a>) stock increased by 8.45% to $2.18. </li>
<li>PEDEVCO (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PED#AMEX">PED</a>) stock rose 7.59% to $0.71. The market value of their outstanding shares is at $64.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BP Prudhoe Bay Royalty Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BPT#NYSE">BPT</a>) shares fell 21.5% to $0.62 during Tuesday's pre-market session. The company's market cap stands at $13.2 million. </li>
<li>Leishen Energy Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NASDAQ">LSE</a>) shares decreased by 13.05% to $5.8. The company's market cap stands at $98.7 million. </li>
<li>Dawson Geophysical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWSN#NASDAQ">DWSN</a>) shares decreased by 10.35% to $2.6. The company's market cap stands at $80.5 million. </li>
<li>Marine Petroleum Tr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARPS#NASDAQ">MARPS</a>) stock decreased by 10.0% to $5.4. The market value of their outstanding shares is at $10.8 million. </li>
<li>Stak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAK#NASDAQ">STAK</a>) shares fell 9.96% to $2.08. The market value of their outstanding shares is at $23.7 million. </li>
<li>Sky Quarry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYQ#NASDAQ">SKYQ</a>) shares declined by 6.48% to $0.82. The market value of their outstanding shares is at $17.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-energy-stocks/" title="www.benzinga.com/money/best-energy-stocks/">www.benzinga.com/money/best-energy-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DWSN

GEOS

HUSA

INDO

MARPS

SKYQ

STAK

TMDE

USEG

12 Energy Stocks Moving In Tuesday's Pre-Market Session

INVZ

Innoviz Technologies Signs Statement of Development Work Agreement With A Passenger Automotive Manufacturer To Supply LiDAR Units

Expanded alliance combines Lisata's drug development expertise with GATC's AI-powered Multiomics Advanced Technology&#xAE; platform to accelerate and improve success rates of next-generation drug development
Lisata to lead development efforts to advance GATC's AI-discovered therapeutic for opioid use disorder into human clinical trials early in 2026
BASKING RIDGE, N.J. and IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and GATC Health Corp. ("GATC"), a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced a strategic alliance designed to accelerate and improve the success rate of the traditional drug development process.

LSTA

Lisata Therapeutics And GATC Health Announce Strategic Alliance To Accelerate And Improve Success Rate Of Traditional Drug Development Process

Marker Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker's lead Multi-Antigen Recognizing (MAR)-T cell therapy.
MT-601 is currently being investigated in the Phase 1 APOLLO study in patients with lymphoma who relapsed after anti-CD19 chimeric antigen receptor (CAR)-T cell therapy or for whom anti-CD19 CAR-T cell therapy is not an option (<a href="https://www.globenewswire.com/Tracker?data=Qe_dx69ERis4suOeZax4PPU9fEvzCNEqL2vvY5Iew3aD8J_SYUdrRmb8DvZwp4LgHdlYotbdtNiwQfe-M0f9Uwj1qOh_AEdNCsnj7FgmoB8=">clinicaltrials.gov</a> identifier: NCT05798897). Marker previously reported a favorable safety profile and objective responses in 7 out of 9 study participants (78%), with 4 participants demonstrating complete response (44.4%) as early as 4 weeks after infusion of MT-601 (<a href="https://www.globenewswire.com/Tracker?data=Q4fHSTzZSw8mxNchU0UEEDgRUABe6o1xDvlYJQuVv_5gQIUBkxil9Ng39EzKUU5-0Xjll5asofc4UrRLbJTwf2EB_OUxCEP0hwTDwfvWQvp3YckiyRR1beGsuEI6M3b3JsMGLocdPdskgmcW33MQq-2zriqYrTN6GDccGogtVteRibgkVMU8q05qtkR5XB5ZpS2I1js7dGESyynn7A7zYNHKJfkaMHJZI1KYy6RzKZBZSiZ--sugPEehRTywsikL">Press Release, December 19, 2024</a>).
Under the agreement, Cellipont will provide technology transfer and cGMP manufacturing services to support the scale-up and production of MT-601 for Marker's APOLLO study. The collaboration between Marker and Cellipont is designed to accelerate clinical supply and lay the foundation for a potential pivotal trial and commercial readiness.

MRKR

Marker Therapeutics Collaborates With Cellipont Bioservices To Accelerate cGMP Manufacturing Of MT-601 MAR-T Cell Therapy For Lymphoma

Semiconductor specialist Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) easily beat the Monday morning blues with a gargantuan leap in the market. When the dust cleared, AMD stock was up nearly 9% over the prior session. Catapulting sentiment were unconfirmed rumors that the tech giant scored a "<a href="https://www.benzinga.com/trading-ideas/movers/25/06/45955190/amd-stock-is-soaring-monday-whats-going-on">GPU win</a>" with Amazon.com Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) namesake cloud computing platform.
As a result, Piper Sandler analyst Harsh Kumar maintained an Overweight rating and raised AMD's price target to $140 (from $125). Last week, the expert highlighted product launches at the company's "Advancing AI" event. Most notably, the industry was abuzz regarding the<a href="https://www.benzinga.com/markets/tech/25/06/45919591/amd-challenges-nvidias-ai-dominance-with-new-helios-server-as-openai-ceo-sam-altman-confirms-chatgpt-will-use-lisa-su-led-tech-giants-latest-chips-future-of-ai-is-not-going-to-be-built-b"> Helios rack</a>, a system comprising 72 advanced graphics processors for the purpose of powering data centers.
Still, with so much enthusiasm baked into AMD stock, investors may wonder if there are additional supporting narratives. Primarily, the bulls will likely point to the continued expansion of machine intelligence. Earlier this month, Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) generated headlines on news that it is considering a<a href="https://www.benzinga.com/m-a/25/06/45839465/zuckerbergs-ai-push-expands-meta-weighs-10b-stake-in-scale-ai"> multi-billion-dollar investment</a> into Scale AI, which helps companies train AI models.
Per a Bloomberg report, the investment could top $10 billion in value, reflecting sustained growth in the digital automation realm. Subsequently, interest in AI may help boost GPU sales.
Another positive storyline again comes from Amazon. Just recently, the e-commerce juggernaut announced plans to invest the equivalent of approximately $13.02 billion through 2029 to<a href="https://www.benzinga.com/markets/equities/25/06/45943758/amazon-commits-13-billion-to-expand-australias-ai-data-center-infrastructure"> expand its data center infrastructure</a> across Australia. Again, such fundamental factors lend credence to the belief that Advanced Micro can benefit from increased demand for its data center products.
Still, every investment carries risks, and AMD stock is no exception. While Advanced Micro has made significant progress in the fabless semiconductor realm, it's an arena dominated by Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>). It's also not particularly close. At the time of writing, Nvidia commands a market capitalization of $3.53 trillion. In contrast, AMD is looking at just under $205 billion.
Another point to consider is that the personal computer market is<a href="https://www.pcworld.com/article/2581409/the-pc-market-grew-only-1-3-in-2024.html"> mature</a>. In particular, consumer PC sales have slowed since the COVID-19 crisis, thus hurting Advanced Micro's traditional CPU and GPU business. It also doesn't help that the PC market only grew about 1.3% last year, reflecting wider challenges.
The Direxion ETFs: With competing narratives clashing for a popular enterprise, those interested in trading AMD stock may consider Direxion's leveraged and inverse exchange-traded funds. For the bulls, the Direxion Daily AMD Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMUU#NASDAQ">AMUU</a>) seeks the daily investment results of 200% of the performance of AMD stock. On the other end, the Direxion Daily AMD Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMDD#NASDAQ">AMDD</a>) seeks 100% of the inverse performance of the namesake equity.
Primarily, the relevance of these Direxion ETFs focuses on providing a convenient mechanism for speculation. Typically, those interested in leveraged opportunities or short positions must engage the options market. However, these derivative instruments can be incredibly complex. Direxion ETFs, on the other hand, can be bought and sold, much like any other publicly traded security, thus mitigating the learning curve.
Nevertheless, prospective participants should be cognizant of the risks. First, inverse and leveraged ETFs tend to be much more volatile than standard funds tracking benchmark indices. Also, the tracking of a single entity makes it subject to wild swings. Second, Direxion ETFs are designed for exposure lasting no longer than one day. Holding beyond the recommended period may expose traders to value decay due to the daily compounding effect.
The AMUU ETF: Making its public market debut in February of this year, the AMUU ETF is off to a decent start, gaining almost 8%.
<ul class="wp-block-list">
<li>Previously, AMUU was bouncing off the 20-day exponential moving average (EMA), which represented support. With Monday's big pop, the bull fund is firmly above this near-term gauge.</li>
<li>What's encouraging about Monday's jump of 17.5% was that it was also accompanied by a massive spike in volume.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1001" height="635" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262.png" alt="" class="wp-image-952124" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262-300x190.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262-768x487.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></figure>
The AMDD ETF: Also making its debut in February, the AMDD ETF isn't quite as fortunate, losing more than 22% of value.
<ul class="wp-block-list">
<li>Contrary to what was witnessed in the bullish counterpart, the AMDD ETF's 20-day EMA has acted as resistance.</li>
<li>Huge distributive volume accompanied Monday's selloff in AMDD. Moving forward, it likely must regain control of $20 to instill confidence.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1001" height="635" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262.png" alt="" class="wp-image-952123" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262-300x190.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/17080630/image-262-768x487.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></figure>
Featured image by <a href="https://pixabay.com/users/artificialog-1886751/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5250769">ArtificialOG</a> from <a href="https://pixabay.com/photos/amd-ryzen-cpu-processor-pc-chip-5250769/">Pixabay</a>.

Short Ideas

Technicals

ETFs

AMDD

AMUU

AMZN

NVDA

Advanced Micro Devices' Demand Spike Draws Intrigue For Direxion's AMD-Focused Bull And Bear Funds

Weight Loss drug maker Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has agreed to acquire Verve Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>), a Boston-based clinical-stage company developing genetic <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45968442/lilly-to-acquire-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovasc" rel="noreferrer noopener">medicines for cardiovascular disease</a>.
Verve&#8217;s lead program (VERVE-102) is a potential first-in-class in vivo gene editing medicine targeting PCSK9, a gene linked to <a href="https://www.benzinga.com/general/health-care">cholesterol levels and cardiovascular health</a>.
The treatment may be applicable for people who have heterozygous familial hypercholesterolemia (HeFH), a subset of ASCVD that affects 1 in 250 people in the general population, as well as certain patients with premature coronary artery disease (CAD).
Also Read: <a href="https://www.benzinga.com/news/health-care/25/06/45947852/eli-lilly-launches-flat-pricing-for-zepbound-capping-monthly-cost-at-499" target="_blank" rel="noreferrer noopener">Eli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499</a>
VERVE-102 is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration.
In April, Verve Therapeutics released initial data from the Heart-2 Phase <a target="_blank" href="https://www.benzinga.com/25/04/44793762/verve-therapeutics-touts-positive-data-from-gene-editing-medicine-to-lower-cholesterol-after-single-dose" rel="noreferrer noopener">1b trial of VERVE-102</a>.
VERVE-102 was well-tolerated among 14 participants across three dose levels. No treatment-related serious adverse events (SAEs) and no clinically significant laboratory abnormalities were observed.
A single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 protein (regulates cholesterol metabolism) levels and LDL-C, with a mean reduction in blood LDL-C of 53% and a maximum LDL-C reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.
Lilly has offered to purchase Verve for $10.50 per share in cash, an aggregate of approximately $1.0 billion, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash, an aggregate of up to approximately $1.3 billion).
CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 trial on or before the tenth anniversary of closing or termination of the CVR.
The transaction is expected to close in the&nbsp;third quarter of 2025.
The purchase price payable at closing represents a premium of approximately 113% to the 30-day volume-weighted average trading price of Verve&#8217;s common stock ended on June 16, 2025, the last trading day before the deal announcement.
Price Action: LLY stock is down 0.89% at $800.42, and VERV stock is up 75.9% at $11.03 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45263363/crispr-therapeutics-data-provides-promising-balance-rfk-jr-appointee" target="_blank" rel="noreferrer noopener">CRISPR Therapeutics&#8217; Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst</a></li>
</ul>
Image via Shutterstock

Large Cap

Health Care

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition

Press Releases

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

Financing

NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer's Disease and Reinforcing Platform's Strength Across Neurological Disorders

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home

Management

NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

Legal

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections  Using gaseous Nitric Oxide (gNO)

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

Comments

Beyond Air

空売り

Beyond Air (NASDAQ:XAIR) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル